KPV vs LL-37
A side-by-side research comparison of KPV and LL-37 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | KPV | LL-37 |
|---|---|---|
| Full name | Lysine-Proline-Valine Tripeptide | Cathelicidin Antimicrobial Peptide LL-37 |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Inhibits NF-kB signaling pathway, reduces pro-inflammatory cytokine production (TNF-α, IL-6), and modulates immune cell activation. | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. |
| Molecular weight | 342.43 Da | 4493.33 Da |
| Half-life | ~2-3 hours | ~4-6 hours |
| Bioavailability | ~60-70% oral; higher subcutaneous | Variable by route; topical and injectable |
| Typical dose | 200-500 mcg per dose | 50-100 mcg |
| Frequency | 1-2x daily | Daily |
| Route | Oral, topical, or subcutaneous | Topical or subcutaneous injection |
KPV reported benefits
- Potent anti-inflammatory
- Gut inflammation reduction
- Skin condition improvement
- Immune modulation
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
Related comparisons
Research and educational reference only. Not medical advice.